Bausch Health Companies Inc. Restructuring and Related Cost, Incurred Cost
Bausch Health Companies Inc. (BHC) reported Restructuring and Related Cost, Incurred Cost of $62.30 million for the 3-month period ending 2012-03-31, per its 10-Q filed 2013-05-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostIncurredCost · last filed 2013-05-03
- Bausch Health Companies Inc. restructuring and related cost, incurred cost for the quarter ending 2012-03-31 was $62.30M.
- Bausch Health Companies Inc. restructuring and related cost, incurred cost for the quarter ending 2011-09-30 was $11.50M.
- Bausch Health Companies Inc. restructuring and related cost, incurred cost for the quarter ending 2011-06-30 was $7.10M.
| Period end | Restructuring and Related Cost, Incurred Cost 3 month | Restructuring and Related Cost, Incurred Cost 6 month | Restructuring and Related Cost, Incurred Cost 9 month |
|---|---|---|---|
| 2012-03-31 | $62.30M 10-Q · filed 2013-05-03 | ||
| 2011-09-30 | $11.50M 10-Q · filed 2011-11-04 | $18.60M derived: sum of 2 quarters · filed 2011-11-04 | $17.40M 10-Q · filed 2011-11-04 |
| 2011-06-30 | $7.10M 10-Q · filed 2011-08-08 | $7.10M 10-Q · filed 2011-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |